(Hong Kong, 12 December 2023) – Hong Kong Science and Technology Parks Corporation (HKSTP) and Simcere Pharmaceutical Group Limited (Simcere; 2096.HK), today announced the opening of the Simcere ‘Hong Kong Collaborative Innovation Center’ at the Hong Kong Science Park. HKSTP will join hands with Simcere to leverage Hong Kong's scientific research capabilities, talent and global access and further enhance Hong Kong's capabilities in the research and development (R&D) and translation of innovative drugs, contributing to pharmaceutical innovation in the Greater Bay Area (GBA) and the country.

Ir Dr H.L. Yiu, Chief Corporate Development Officer of HKSTP, said, “With Simcere joining us, it will inject impetus into the biomedical industry, offering more collaboration and innovation opportunities. Under the government’s steadfast support, we believe there will be rapid growth in the biomedical industry over the next five years.”

Mr Gaobo Zhou, Chief Investment Officer of Simcere Pharmaceutical Group, said, “The Simcere ‘Hong Kong Collaborative Innovation Center’ will leverage Hong Kong's unique advantages in its connection with the GBA, robust scientific research prowess, abundant talent pool and international capital market, backed by strong policy support to accelerate our pipelines in Hong Kong and global market.”

Simcere is an innovation-driven, full-value chain pharmaceutical company. It was listed on the Hong Kong Stock Exchange (HKEX) in 2020 and became the first batch of strategic enterprises of the Office for Attracting Strategic Enterprises (OASES) in October 2023. In addition to Hong Kong, Simcere has also established four innovation centers in Shanghai, Nanjing, Beijing and Boston.